SG160248A1 - Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells - Google Patents

Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells

Info

Publication number
SG160248A1
SG160248A1 SG200806945-2A SG2008069452A SG160248A1 SG 160248 A1 SG160248 A1 SG 160248A1 SG 2008069452 A SG2008069452 A SG 2008069452A SG 160248 A1 SG160248 A1 SG 160248A1
Authority
SG
Singapore
Prior art keywords
stem cells
characterize
monoclonal antibodies
human embryonic
induced pluripotent
Prior art date
Application number
SG200806945-2A
Other languages
English (en)
Inventor
Boon Hwa Andre Choo
Kah Weng Steve Oh
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG200806945-2A priority Critical patent/SG160248A1/en
Priority to CN2009801458029A priority patent/CN102216445A/zh
Priority to EP09814853.9A priority patent/EP2331675B1/fr
Priority to AU2009292707A priority patent/AU2009292707A1/en
Priority to JP2011527781A priority patent/JP2012502653A/ja
Priority to PCT/SG2009/000346 priority patent/WO2010033084A1/fr
Priority to CA2739368A priority patent/CA2739368A1/fr
Priority to US13/119,486 priority patent/US20110171183A1/en
Publication of SG160248A1 publication Critical patent/SG160248A1/en
Priority to IL211764A priority patent/IL211764A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
SG200806945-2A 2008-09-18 2008-09-18 Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells SG160248A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SG200806945-2A SG160248A1 (en) 2008-09-18 2008-09-18 Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells
CN2009801458029A CN102216445A (zh) 2008-09-18 2009-09-17 诱导多能干细胞的标记
EP09814853.9A EP2331675B1 (fr) 2008-09-18 2009-09-17 Marqueurs de cellules souches pluripotentes induites
AU2009292707A AU2009292707A1 (en) 2008-09-18 2009-09-17 Markers of induced pluripotent stem cells
JP2011527781A JP2012502653A (ja) 2008-09-18 2009-09-17 人工多能性幹細胞のマーカー
PCT/SG2009/000346 WO2010033084A1 (fr) 2008-09-18 2009-09-17 Marqueurs de cellules souches pluripotentes induites
CA2739368A CA2739368A1 (fr) 2008-09-18 2009-09-17 Marqueurs de cellules souches pluripotentes induites
US13/119,486 US20110171183A1 (en) 2008-09-18 2009-09-17 Markers of Induced Pluripotent Stem Cells
IL211764A IL211764A0 (en) 2008-09-18 2011-03-16 Markers of induced pluripotent stem cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG200806945-2A SG160248A1 (en) 2008-09-18 2008-09-18 Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells

Publications (1)

Publication Number Publication Date
SG160248A1 true SG160248A1 (en) 2010-04-29

Family

ID=42039750

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200806945-2A SG160248A1 (en) 2008-09-18 2008-09-18 Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells

Country Status (9)

Country Link
US (1) US20110171183A1 (fr)
EP (1) EP2331675B1 (fr)
JP (1) JP2012502653A (fr)
CN (1) CN102216445A (fr)
AU (1) AU2009292707A1 (fr)
CA (1) CA2739368A1 (fr)
IL (1) IL211764A0 (fr)
SG (1) SG160248A1 (fr)
WO (1) WO2010033084A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4166652A1 (fr) 2009-11-12 2023-04-19 Technion Research & Development Foundation Ltd. Milieux de culture, cultures cellulaires et procédés de culture de cellules souches pluripotentes dans un état indifférencié
US9334324B2 (en) 2010-02-04 2016-05-10 Agency For Science, Technology And Research Podocalyxin-like-protein-1 binding antibody molecule
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
CN109112097A (zh) * 2010-06-16 2019-01-01 米纳瓦生物技术公司 重编程癌细胞
SG187163A1 (en) * 2010-07-21 2013-02-28 Agency Science Tech & Res Methods for identifying candidate cytotoxic antibody molecules
EP2615176A1 (fr) 2012-01-11 2013-07-17 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Nouvelles particules de lentivirus pseudotypées et leur utilisation dans la transduction ciblée in vitro de cellules souches embryonnaires humaines pluripotentes indifférenciées et cellules souches pluripotentes induites
US10155929B2 (en) * 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
MX2015008619A (es) * 2012-12-31 2016-01-12 Janssen Biotech Inc Suspension y agrupamiento de celulas humanas pluripotentes para la diferenciacion a celulas endocrinas pancreaticas.
EP3170893B1 (fr) * 2014-07-16 2021-03-10 Kyoto University Procédé d'extraction de cellules différenciées
CN107075473B (zh) * 2014-11-07 2021-07-13 国立大学法人大阪大学 其中未分化细胞被去除的分化诱导的细胞群、其用途及其制备方法
EP3273241B1 (fr) 2015-03-17 2019-10-30 National Institute of Advanced Industrial Science and Technology Procédé et kit pour détecter une cellule souche
US20180258400A1 (en) * 2015-09-15 2018-09-13 Agency For Science, Technology And Research (A*Star) Derivation of liver organoids from human pluripotent stem cells
KR101781693B1 (ko) * 2015-09-24 2017-09-26 서울대학교병원 심장내막 유래 성체줄기세포로부터 제조된 유도만능 줄기세포의 심혈관계 세포로의 분화방법 및 이의 용도
WO2019141878A1 (fr) * 2018-01-22 2019-07-25 Sistemic Scotland Ltd Dosage de contamination cellulaire
TW201938788A (zh) * 2018-03-06 2019-10-01 美商歐瑞３恩公司 用於軟骨修復之源自iPSC之細胞組合物及相關系統與方法
TW202043459A (zh) * 2018-12-26 2020-12-01 中央研究院 調節萬能性幹細胞之潛能的方法及應用
CN111996241A (zh) * 2020-08-13 2020-11-27 北京呈诺医学科技有限公司 一种使用ESRG基因作为通用标记基因的iPSC残留检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505097A (ja) * 1998-03-03 2002-02-19 アブジェニックス インク． 治療薬としてのｃｄ１４７結合分子
US20050281828A1 (en) * 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
JP4904153B2 (ja) * 2003-06-20 2012-03-28 アキシオジェネシス エージー 胚性幹（ｅｓ）細胞系での組織モデリング
WO2006088867A2 (fr) * 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Procede pour l'expansion de cellules souches
EP2208786B1 (fr) * 2005-12-13 2018-08-01 Kyoto University Facteur de reprogrammation nucléaire
EP1994144B1 (fr) 2006-03-06 2017-11-22 Agency for Science, Technology and Research Procedes d'identification de cellules souches embryonnaires humaines et expression de la proteine de type podocalyxine (podxl)
US20060294607A1 (en) * 2006-03-29 2006-12-28 Applera Corporation Human podocalyxin alternative-spliced forms and uses thereof
US20070259423A1 (en) * 2006-05-02 2007-11-08 Jon Odorico Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
EP2055772A4 (fr) * 2006-08-28 2009-12-30 Univ Matsumoto Dental Procédé d'inhibition du développement de tératome

Also Published As

Publication number Publication date
EP2331675A4 (fr) 2012-06-13
EP2331675B1 (fr) 2018-05-16
WO2010033084A1 (fr) 2010-03-25
CN102216445A (zh) 2011-10-12
IL211764A0 (en) 2011-06-30
AU2009292707A1 (en) 2010-03-25
US20110171183A1 (en) 2011-07-14
CA2739368A1 (fr) 2010-03-25
EP2331675A1 (fr) 2011-06-15
JP2012502653A (ja) 2012-02-02

Similar Documents

Publication Publication Date Title
SG160248A1 (en) Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MY165273A (en) Anti-cd48 antibodies and uses thereof
MY178142A (en) Anti-phf-tau antibodies and their uses
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201591198A1 (ru) Антитела к gdf15
TN2012000040A1 (en) High affinity human antibodies to human angiopoietin -2
MX2011012060A (es) Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-miloide.
IN2014MN01642A (fr)
MX341344B (es) Agentes dirigidos a cd138 y sus usos.
TN2012000555A1 (en) Antibodies to human gdf8
EP2582722A4 (fr) Anticorps contre gd2
EA201792376A2 (ru) Молекулы анти-gcc антитела и соответствующие композиции и способы
MY165038A (en) Humanized antibodies that recognize alpha-synuclein
UA113397C2 (xx) Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3
MY184241A (en) Human antibodies to gfr?3 and methods of use thereof
UA104663C2 (en) Antibody binding to cd127
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
GB201109238D0 (en) Antibodies
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EA201101303A1 (ru) Молекулы антител, обладающие связывающей специфичностью в отношении il-13 человека
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
MX2013002960A (es) Composiciones de anticuerpo y metodos de uso.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
UA110051C2 (uk) Антитіло, яке зв'язує tgf-альфа та епірегулін